Phaseline

Targets › HBSAG

HBSAG: drug programs, companies and trials

3 programs from 3 companies in 4 trials: 3 Phase 1, 1 Phase 4; Infectious disease; next expected readout Jul 2027.

Open in Phaseline: the race on HBSAG, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University Health Network, TorontoHepatitis B Immune Globulin
Surface antigen (HBsAg) binding agent
HBSAGPhase 4Hepatitis B Virus (HBV)Aug 2027
Rockefeller UniversityHepB mAb19
anti-HBV surface antigen (HBsAg) monoclonal antibody targeting the 'a' determinant
HBSAGPhase 1Hepatitis b VirusJul 2027
Aarhus University HospitalHepB mAb19
Hepatitis B surface antigen (HBsAg) binding monoclonal antibody
HBSAGPhase 1Hepatitis B; Hepatitis D, ChronicAug 2027

Conditions

Hepatitis b Virus (1) Hepatitis B (1) Hepatitis D, Chronic (1) Hepatitis B Virus (HBV) (1)

Modalities

protein or peptide (1), small molecule (1), mixed (1)

Companies

Rockefeller University (1) Aarhus University Hospital (1) University Health Network, Toronto (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.